Marinus Pharmaceuticals Inc.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2022 | $1 M | No. 4 | Under $2 million | equity | SEC | |
| Dec 2019 | $30 M | No. 3 | $10 to $50 million | equity | SEC | |
| Dec 2012 | $22 M | No. 2 | $10 to $50 million | equity | SEC | |
| Apr 2009 | $20 M | No. 1 | $10 to $50 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Marinus Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2022).
SEC Form D · Apr 2022
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Apr 2022
That is all the official record says: Marinus Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: the address on record now leads to another company's site.
Investors#
8 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Canaan Partners VII LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2014) | SEC Form 3 |
| Canaan VII L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2014) | SEC Form 3 |
| Domain Partners VI, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| DP VI Associates, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Sofinnova Management VI, L.L.C. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Sofinnova Venture Affiliates VI LP | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Sofinnova Venture Partners VI GmbH & Co. KG | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Sofinnova Venture Partners VI L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 7 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Joseph E. Hulihan, M.D. | Chief Medical Officer | Apr 2022 |
| Martha E. Manning, Esq. | Vice President, General Counsel, and Secretary | Apr 2022 |
| Scott Braunstein, M.D. | Chief Executive Officer and Director | Apr 2022 |
| Steven E. Pfanstiel | Chief Financial Officer | Apr 2022 |
| Edward F. Smith | Executive officer | Dec 2019 |
| Joe F. Hulihan, MD | Executive officer | Dec 2019 |
| Scott Braunstein, MD | Executive officer | Dec 2019 |
| Christopher M. Cashman | Executive officer | Jul 2013 |
| Alan Barber | ACTING CHIEF FINANCIAL OFFICER AND ASSISTANT TREASURER | Apr 2009 |
| Cable Stuart | ASSISTANT SECRETARY | Apr 2009 |
| John Krayacich | CHIEF EXECUTIVE OFFICER, PRESIDENT AND TREASURER | Apr 2009 |
| Kenneth Shaw | VICE PRESIDENT, SECRETARY AND ASSISTANT TREASURER | Apr 2009 |
| Charles E. Austin | Director | Apr 2022 |
| Elan R. Ezickson | Director | Apr 2022 |
| Michael R. Dougherty | Director | Apr 2022 |
| Nicole E. Vitullo | Director, Chairman of the Board | Apr 2022 |
| Santiago E. Arroyo, M.D., Ph.D. | Director | Apr 2022 |
| Saraswathy M. Nochur, Ph.D. | Director | Apr 2022 |
| Scott Braunstein, M.D. | Chief Executive Officer and Director | Apr 2022 |
| Seth H.Z. Fischer | Director | Apr 2022 |
| Tim M. Mayleben | Director | Apr 2022 |
| Elan M. Ezickson | Director | Dec 2019 |
| Enrique J. Carrazana, MD | Director | Dec 2019 |
| Nicole M. Vitullo | Director | Dec 2019 |
| Scott Braunstein, MD | Director | Dec 2019 |
| Anand T. Mehra, M.D. | Director | Jul 2013 |
| Anton M. Gopka | Director | Jul 2013 |
| Christopher M. Cashman | Director | Jul 2013 |
| Harry M. Penner | Director | Jul 2013 |
| Harry T. Rein | Director | Jul 2013 |
| Nicole T. Vitullo | Director | Jul 2013 |
| Stephen M. Bloch, M.D. | Director | Jul 2013 |
| Timothy M. Mayleben | Director | Jul 2013 |
| Anand Mehra | Director | Apr 2009 |
| Harry H. Penner, Jr. | Director | Apr 2009 |
| John Krayacich | CHIEF EXECUTIVE OFFICER, PRESIDENT AND TREASURER | Apr 2009 |
| Nicole Vitullo | Director | Apr 2009 |
| Stephen Bloch | CHAIRMAN OF THE BOARD OF DIRECTORS | Apr 2009 |
| Timothy Mayleben | Director | Apr 2009 |
About
Company in Radnor, United States.